IDEXX Laboratories, Inc. (NASDAQ:IDXX) CEO Jonathan W. Ayers sold 18,000 shares of the firm’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $153.61, for a total transaction of $2,764,980.00. Following the completion of the sale, the chief executive officer now directly owns 1,064,573 shares of the company’s stock, valued at $163,529,058.53. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded up $2.68 during midday trading on Friday, reaching $154.08. 746,200 shares of the company were exchanged, compared to its average volume of 713,709. IDEXX Laboratories, Inc. has a one year low of $112.67 and a one year high of $173.01. The stock has a market cap of $13,510.00, a PE ratio of 50.98, a P/E/G ratio of 2.29 and a beta of 0.46. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.05. The business had revenue of $492.00 million during the quarter, compared to analyst estimates of $492.94 million. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. IDEXX Laboratories’s revenue was up 9.7% compared to the same quarter last year. During the same period last year, the business earned $0.62 EPS. research analysts anticipate that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/17/idexx-laboratories-inc-idxx-ceo-jonathan-w-ayers-sells-18000-shares-of-stock.html.

A number of research analysts recently issued reports on IDXX shares. CL King raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target for the company in a research report on Friday, July 28th. BidaskClub cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Stifel Nicolaus reissued a “buy” rating and set a $185.00 price target on shares of IDEXX Laboratories in a research report on Wednesday, August 2nd. Canaccord Genuity reissued a “buy” rating and set a $180.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, August 22nd. Finally, Bank of America Corporation raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target for the company in a research report on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. IDEXX Laboratories currently has an average rating of “Hold” and a consensus target price of $173.67.

A number of large investors have recently added to or reduced their stakes in IDXX. Koch Industries Inc. increased its stake in IDEXX Laboratories by 44,533.1% during the 2nd quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock valued at $1,391,000 after purchasing an additional 1,396,113 shares in the last quarter. Janus Henderson Group PLC increased its stake in IDEXX Laboratories by 486.4% during the 2nd quarter. Janus Henderson Group PLC now owns 1,131,902 shares of the company’s stock valued at $182,711,000 after purchasing an additional 938,888 shares in the last quarter. BlackRock Inc. increased its stake in IDEXX Laboratories by 10.5% during the 2nd quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock valued at $1,146,142,000 after purchasing an additional 673,347 shares in the last quarter. Old Mutual Global Investors UK Ltd. bought a new stake in IDEXX Laboratories during the 2nd quarter valued at about $83,723,000. Finally, Arrowstreet Capital Limited Partnership increased its stake in IDEXX Laboratories by 42.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock valued at $211,567,000 after purchasing an additional 392,790 shares in the last quarter. Institutional investors and hedge funds own 88.03% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Stock Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related stocks with our FREE daily email newsletter.